OSE Immunotherapeutics (LTS:0RAD) Other Current Liabilities: €9.54 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RAD OSE Immunotherapeutics SA LTS:0RAD
51 GF Score
Price €3.27
GF Value €1.51
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Other Current Liabilities?

OSE Immunotherapeutics LTS:0RAD +0.25% 51 Other Current Liabilities is €9.54 Mil as of Dec. 2025. GuruFocus rates LTS:0RAD with a GF Score™ of 51/100 and a GF Value™ of €1.51 (Significantly Overvalued). The stock has 6 warning signs investors should review.

OSE Immunotherapeutics's other current liabilities for the quarter that ended in Dec. 2025 was €9.54 Mil.

OSE Immunotherapeutics's quarterly other current liabilities declined from Dec. 2024 (€8.77 Mil) to Jun. 2025 (€8.41 Mil) but then increased from Jun. 2025 (€8.41 Mil) to Dec. 2025 (€9.54 Mil).

OSE Immunotherapeutics's annual other current liabilities increased from Dec. 2023 (€5.03 Mil) to Dec. 2024 (€8.77 Mil) and increased from Dec. 2024 (€8.77 Mil) to Dec. 2025 (€9.54 Mil).

OSE Immunotherapeutics Other Current Liabilities Related Terms

OSE Immunotherapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for OSE Immunotherapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics Other Current Liabilities Chart

OSE Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.27 7.26 5.03 8.77 9.54

OSE Immunotherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.03 2.90 8.77 8.41 9.54
LTS:0RAD
51GF Score
OSE Immunotherapeutics SA LTS:0RAD
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OSE Immunotherapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €9.54 Mil mean?
OSE Immunotherapeutics (LTS:0RAD) has a Other Current Liabilities of €9.54 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on OSE Immunotherapeutics.
Is OSE Immunotherapeutics' Other Current Liabilities too high?
OSE Immunotherapeutics' current Other Current Liabilities is €9.54 Mil. Overall, OSE Immunotherapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' Other Current Liabilities compare to VRTX and REGN?
OSE Immunotherapeutics' Other Current Liabilities of €9.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on OSE Immunotherapeutics. OSE Immunotherapeutics's current Other Current Liabilities is €9.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (LTS:0RAD) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.51, compared to a current price of €3.27 — trading 116.6% above its estimated fair value. The current Other Current Liabilities is €9.54 Mil. OSE Immunotherapeutics' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For OSE Immunotherapeutics (LTS:0RAD), the current Other Current Liabilities is €9.54 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OSE Immunotherapeutics (LTS:0RAD) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of €3.27 is trading 116.6% above its estimated GF Value™ of €1.51. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for LTS:0RAD:

  • Other Current Liabilities: €9.54 Mil
  • GF Value™: €1.51 vs. price of €3.27 (116.6% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the LTS:0RAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OSE Immunotherapeutics Business Description

Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
51GF Score

Get the complete analysis for LTS:0RAD

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.27
Price
€1.51
GF Value